Lakefront Biotherapeutics (LKFT) Non Operating Income (2016 - 2024)
Lakefront Biotherapeutics (LKFT) posted quarterly Non Operating Income of $4.5 million for Q4 2024, up 103.25% quarter-over-quarter from -$138.0 million in Q4 2022.
Lakefront Biotherapeutics (LKFT) Non Operating Income (2016 - 2024) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Non Operating Income for 8 consecutive years, with $4.5 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Non Operating Income changed N/A year-over-year to $4.5 million; the TTM figure through Dec 2024 stood at -$57.1 million (changed N/A YoY), while the FY2024 annual figure was $4.5 million, up 734.27% from the prior year.
- Non Operating Income advanced to $4.5 million in Q4 2024 per LKFT's latest filing, from -$138.0 million in the prior quarter.
- Across five years, Non Operating Income topped out at $60.3 million in Q3 2022 and bottomed at -$138.0 million in Q4 2022.
- Historically, Non Operating Income has averaged -$18.9 million across 4 years, with a median of $4.5 million in 2024.
- Annual changes were most pronounced in 2020 — Non Operating Income plunged 1086.57% — and 2022, when it surged 273.2%.
- Lakefront Biotherapeutics' Non Operating Income stood at -$37.6 million in 2020, then jumped by 142.97% to $16.2 million in 2021, then slumped by 954.4% to -$138.0 million in 2022, then jumped by 103.25% to $4.5 million in 2024.
- Business Quant data shows LKFT's Non Operating Income at $4.5 million in Q4 2024, -$138.0 million in Q4 2022, and $60.3 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4.49 Mn |
| Dec 31, 2022 | -138.04 Mn |
| Sep 30, 2022 | 60.29 Mn |
| Sep 30, 2021 | 16.16 Mn |
| Jun 30, 2020 | -37.60 Mn |
| Dec 31, 2019 | -243.77 Mn |
| Jun 30, 2019 | -3.17 Mn |
| Mar 31, 2019 | 5.29 Mn |
| Dec 31, 2018 | 17.80 Mn |
| Sep 30, 2018 | 8.00 Bn |
| Jun 30, 2018 | -8.19 Bn |
| Mar 31, 2018 | -6.37 Mn |
| Sep 30, 2017 | -19.07 Bn |
| Jun 30, 2017 | 17.87 Bn |
| Mar 31, 2017 | -2.54 Mn |
| Jun 30, 2016 | 3.63 Mn |
| Mar 31, 2016 | 58.84 Mn |